These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25749516)

  • 21. A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy.
    Sánchez-Martínez R; Cruz-Gil S; Gómez de Cedrón M; Álvarez-Fernández M; Vargas T; Molina S; García B; Herranz J; Moreno-Rubio J; Reglero G; Pérez-Moreno M; Feliu J; Malumbres M; Ramírez de Molina A
    Oncotarget; 2015 Nov; 6(36):38719-36. PubMed ID: 26451612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer.
    Peng J; Wang Z; Chen W; Ding Y; Wang H; Huang H; Huang W; Cai S
    Int J Colorectal Dis; 2010 Nov; 25(11):1277-85. PubMed ID: 20706727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
    Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
    Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
    Pagès F; Kirilovsky A; Mlecnik B; Asslaber M; Tosolini M; Bindea G; Lagorce C; Wind P; Marliot F; Bruneval P; Zatloukal K; Trajanoski Z; Berger A; Fridman WH; Galon J
    J Clin Oncol; 2009 Dec; 27(35):5944-51. PubMed ID: 19858404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
    Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
    Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.
    Masuda T; Ishikawa T; Mogushi K; Okazaki S; Ishiguro M; Iida S; Mizushima H; Tanaka H; Uetake H; Sugihara K
    Int J Oncol; 2016 Mar; 48(3):975-82. PubMed ID: 26783118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3'UTR Polymorphism in ACSL1 Gene Correlates with Expression Levels and Poor Clinical Outcome in Colon Cancer Patients.
    Vargas T; Moreno-Rubio J; Herranz J; Cejas P; Molina S; Mendiola M; Burgos E; Custodio AB; De Miguel M; Martín-Hernández R; Reglero G; Feliu J; Ramírez de Molina A
    PLoS One; 2016; 11(12):e0168423. PubMed ID: 27992526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
    Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
    Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
    Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
    Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients.
    Zhang Q; Wang XQ; Wang J; Cui SJ; Lou XM; Yan B; Qiao J; Jiang YH; Zhang LJ; Yang PY; Liu F
    Oncotarget; 2015 Jun; 6(17):15095-110. PubMed ID: 25945835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A robust gene signature for the prediction of early relapse in stage I-III colon cancer.
    Dai W; Li Y; Mo S; Feng Y; Zhang L; Xu Y; Li Q; Cai G
    Mol Oncol; 2018 Apr; 12(4):463-475. PubMed ID: 29377588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
    Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
    Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In situ validation of an intestinal stem cell signature in colorectal cancer.
    Ziskin JL; Dunlap D; Yaylaoglu M; Fodor IK; Forrest WF; Patel R; Ge N; Hutchins GG; Pine JK; Quirke P; Koeppen H; Jubb AM
    Gut; 2013 Jul; 62(7):1012-23. PubMed ID: 22637696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of p53 messenger ribonucleic acid expression in patients after curative resection for stage I to III colorectal cancer: association with colon cancer stem cell markers.
    Huh JW; Kim HR; Kim YJ
    J Am Coll Surg; 2013 Jun; 216(6):1063-9. PubMed ID: 23571142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
    Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
    J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.